publication date: Jun. 15, 2018

Letter to the Editor

MammaPrint has remained consistent and credible since introduction more than a decade ago

William Audeh2

William Audeh

Chief medical officer, Agendia

 

To the Editor:

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question.

The recent results from the TAILORx clinical trial evaluating Oncotype DX are important for patients and their oncologists, but they also raised questions and concerns regarding the appropriate treatment strategies for certain women with early-stage breast cancer, and the results should be carefully evaluated for each group of patients.

Patients who have had MammaPrint genomic testing should be assured that the findings from the TAILORx trial do not change or in any way impact the MammaPrint test, which has remained consistent and credible since the test was introduced more than a decade ago, and for which the MINDACT trial provided the highest level of evidence in 2016.

To best understand the utility for treatment decisions, it is important to recognize the differences between the TAILORx trial and the MINDACT trial, the landmark trial supporting the clinical utility of MammaPrint.

 

For clinically low-risk women, TAILORx confirmed lack of chemotherapy benefit

In post-menopausal women over the age of 50 with small (1-2 cm), low-grade and lymph-node negative tumors and … Continue reading MammaPrint has remained consistent and credible since introduction more than a decade ago

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.